Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 8/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15727246 | 0.93 | SMN1; SMN2 (0.43) | SMN1; SMN2RENNFKB1NFKB2RELA | |
| SCHEMBL15727311 | 0.92 | SMN1; SMN2 (0.39) | SMN1; SMN2RENNFKB1NFKB2RELA | |
| SCHEMBL15727250 | 0.92 | SMN1; SMN2 (0.41) | SMN1; SMN2NFKB1NFKB2RELACTSS | |
| SCHEMBL23736256 | 0.89 | SMN1; SMN2 (0.39) | SMN1; SMN2RENNFKB1NFKB2RELA | |
| SCHEMBL15727302 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2RENNFKB1NFKB2RELA | |
| SCHEMBL7541004 | 0.87 | SMN1; SMN2 (0.48) | SMN1; SMN2NFKB1NFKB2RELACTSS | |
| SCHEMBL28659964 | 0.87 | SMN1; SMN2 (0.48) | SMN1; SMN2NFKB1NFKB2RELACTSS | |
| SCHEMBL615910 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2NFKB1NFKB2RELACTSS | |
| SCHEMBL1604541 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2NFKB1NFKB2RELACTSS | |
| SCHEMBL615909 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2NFKB1NFKB2RELACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309285-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2014081886-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | SMN1; SMN2 1689/4885REN 861/4885NFKB1 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.